Arteriovenous Fistula Clinical Trial
Official title:
IN.PACT™ AV Access Post-Approval Study (PAS002)
Long-term safety will be summarized
Status | Recruiting |
Enrollment | 240 |
Est. completion date | February 2029 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Primary Cohort Inclusion Criteria: - Patient is = 21 years of age - Patient has a mature native AV fistula created = 60 days prior to the index procedure - Patient has a de novo and/or non-stented restenotic lesion located between the arteriovenous anastomosis and axillosubclavian junction - Patient has a target lesion or a tandem lesion that is = 100 mm in length (by visual estimate) Note: Tandem lesions may be included provided they meet all of the following criteria: a. Separated by a gap of = 30 mm (3 cm), b. Total combined lesion length, including 30 mm gap, = 100 mm, c. Able to be treated as a single lesion - Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate) - Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as: Residual stenosis of = 30% AND Absence of a flow limiting dissection or perforation AND No extravasation requiring treatment Primary Cohort Exclusion Criteria: - Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children - Patient is receiving immunosuppressive therapy - Patient has an infected AV access or systemic infection - Patient with hemodynamically significant central venous stenoses that cannot be successfully treated prior to treatment of the target lesion - Patient with target lesion located central to the axillosubclavian junction - Patient has significant arterial inflow lesion requiring treatment more than 2 cm upstream from the anastomosis in the AV access - Patient has presence of pseudoaneurysm or aneurysm requiring treatment at the lesion site - Target lesion is located within a bare metal or covered stent - Patients with known allergies or sensitivities to paclitaxel - Patient with known contraindication, including allergic reaction, or sensitivity to contrast material that cannot be adequately pre-treated - Patient who cannot receive recommended antiplatelet and/or anticoagulant therapy - Patient is enrolled in another investigational drug, device, or biologic study and has not completed the primary endpoint, or was previously enrolled in this study - Patient has a co-morbid condition that, in the judgment of the Investigator, may cause him/her to be non-compliant with the protocol or confound the data interpretation - Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19 Inclusion Criteria for Extended Cohort: - Patient is = 21 years of age Exclusion Criteria for Extended Cohort: - Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19 |
Country | Name | City | State |
---|---|---|---|
United States | Albany Medical College | Albany | New York |
United States | University of Michigan Health System - University Hospital | Ann Arbor | Michigan |
United States | University of Virginia Medical Center | Charlottesville | Virginia |
United States | University of Iowa | Iowa City | Iowa |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Cedars-Sinai Heart Institute | Los Angeles | California |
United States | University of Wisconsin-Madison - Meriter Hospital | Madison | Wisconsin |
United States | NCH Healthcare System | Naples | Florida |
United States | Yale New Haven Hospital | New Haven | Connecticut |
United States | The Mount Sinai Hospital | New York | New York |
United States | MUSC Health Dialysis Access Institute | Orangeburg | South Carolina |
United States | Coastal Vascular and Interventional | Pensacola | Florida |
United States | FirstHealth of the Carolinas | Pinehurst | North Carolina |
United States | Oregon Health & Science University Hospital | Portland | Oregon |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Spartanburg Regional Medical Center | Spartanburg | South Carolina |
United States | Stanford University Medical Center | Stanford | California |
United States | Staten Island University Hospital | Staten Island | New York |
United States | Holy Name Medical Center | Teaneck | New Jersey |
United States | Medstar Washington Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Medtronic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Extended Cohort - Characterize Infections and Infestations Serious Adverse Events | Characterize infections and infestations Serious Adverse Events, including pneumonia. | Through 1-year and all-cause mortality through 5-years post-index procedure | |
Primary | Infection and Infestations Serious Adverse Events | Demonstrate Infection and Infestations Serious Adverse Events, including pneumonia, meets the performance goal of 30% in the primary cohort. | Through 12 months post-index procedure | |
Secondary | Mortality Rate | Determine mortality rate | Through 1, 2, 3, 4, and 5 years post-index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05302505 -
Simulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients
|
N/A | |
Terminated |
NCT01642459 -
The Outcomes of Arteriovenous Fistula Cannulated From Different Direction.
|
N/A | |
Recruiting |
NCT04017806 -
Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation
|
||
Terminated |
NCT03668002 -
Trial of Fistula Versus Graft in Elderly Patients
|
N/A | |
Completed |
NCT06199609 -
Changes in Cardiac Structure and Function After Establishment of Autologous Arteriovenous Fistula
|
||
Recruiting |
NCT04034433 -
Exercise Program for Arteriovenous Fistula Maturation
|
N/A | |
Active, not recruiting |
NCT04629118 -
Intervention With Selution SLR™ Agent Balloon for Endovascular Latent Limus Therapy for Failing AV Fistulas (ISABELLA) Trial
|
||
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Recruiting |
NCT05616104 -
FLEX FIRST Registry Research Protocol
|
||
Recruiting |
NCT03886116 -
Effect of Pre-operative Forearm Exercises on Arterial Venous Fistula Maturation and Blood Flow
|
N/A | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
Completed |
NCT05326321 -
Effect of Virtual Reality Glasses in The Arteriovenous Fistule Cannulation Processon Paın and Patient Satisfaction
|
N/A | |
Recruiting |
NCT03741985 -
Effect of Dumbbell Exercise on Arteriovenous Fistula in Patients With Hemodialysis
|
N/A | |
Terminated |
NCT03566927 -
FLEX®-DCB Dialysis ACCESS Stenosis Study
|
N/A | |
Not yet recruiting |
NCT04393688 -
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula
|
N/A | |
Recruiting |
NCT02447796 -
Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery
|
Phase 4 | |
Terminated |
NCT01321866 -
Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients
|
N/A | |
Not yet recruiting |
NCT03137680 -
Pre-Operative Forearm Exercise On Arteriovenous Fistula Mauration
|
N/A |